XTL BiopharmaceuticalsXTLB -4.82%28 PS Ratio is 296.25 as of Jul. 02, 2026. GuruFocus rates XTLB with a GF Score™ of 28/100. The stock has 4 warning signs investors should review. Among 933 Biotechnology companies, XTL Biopharmaceuticals ranks worse than 107181.03% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, XTL Biopharmaceuticals's share price is $2.37.
XTL Biopharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01. Hence, XTL Biopharmaceuticals's PS Ratio for today is 296.25.
The historical rank and industry rank for XTL Biopharmaceuticals's PS Ratio or its related term are showing as below:
XTLB's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.46 * Ranked among companies with meaningful PS Ratio only.
During the past 13 years, XTL Biopharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 121.20% per year. The lowest was 15.80% per year. And the median was 68.50% per year.
Back to Basics: PS Ratio
XTL Biopharmaceuticals (NAS:XTLB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XTL Biopharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
XTL Biopharmaceuticals's Share Price of today is $2.37.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. XTL Biopharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
XTL Biopharmaceuticals (XTLB) has a PS Ratio of 296.25 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on XTL Biopharmaceuticals and its competitors. According to the industry distribution chart, XTL Biopharmaceuticals ranks #999999 out of 933 companies in the Biotechnology industry.
Is XTL Biopharmaceuticals' PS Ratio too high?
XTL Biopharmaceuticals' current PS Ratio is 296.25. The Biotechnology industry median PS Ratio is 9.46. XTL Biopharmaceuticals' value of 296.25 is 3031.6% above this industry median. Based on the distribution chart, XTL Biopharmaceuticals ranks #999999 out of 933 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, XTL Biopharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #999999 out of 933 companies for PS Ratio. This places XTL Biopharmaceuticals in the lower half of its industry. The industry median PS Ratio is 9.46. XTL Biopharmaceuticals' value of 296.25 is 3031.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.46, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. XTL Biopharmaceuticals's current PS Ratio of 296.25 is 3031.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on XTL Biopharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. XTL Biopharmaceuticals's current PS Ratio is 296.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current PS Ratio of 296.25. The current PS Ratio is 296.25 and 3031.6% above the Biotechnology industry median of 9.46. XTL Biopharmaceuticals' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current PS Ratio is 296.25 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
28GF Score
Get the complete analysis for XTLB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
